{"id":829364,"date":"2025-03-25T08:05:49","date_gmt":"2025-03-25T12:05:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/"},"modified":"2025-03-25T08:05:49","modified_gmt":"2025-03-25T12:05:49","slug":"annovis-to-attend-ad-pd-2025-with-extensive-scientific-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/","title":{"rendered":"Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MALVERN, Pa., March  25, 2025  (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE: ANVS) (&#8220;Annovis&#8221;), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced its participation in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-YxnYm6jrir_194DS7UcP_jU3ubX_cxYzolLwcZTgTTf1qrQx3By01VwWjZNppL1JJ5laNXFZCdArX3qy6vQBw==\" rel=\"nofollow\" target=\"_blank\">AD\/PD\u2122<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kjk3vCrH5-s0e_k8cnBr2OVNedVCgyew7hc3DEqoDihi2SwIjmaykyH27cqxI6PqMeTkYSpJ3qGFWDoZC3zbjg==\" rel=\"nofollow\" target=\"_blank\">\u00a02025<\/a> taking place April 1-5 in Vienna.<\/p>\n<p>&#8220;We are at a pivotal moment in our company\u2019s journey as we have entered the late clinical stages for both Alzheimer\u2019s and Parkinson\u2019s. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications,\u201d commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. \u201cAt this meeting, we will present comprehensive data from our latest Phase 3 PD and Phase 2\/3 AD studies. For Parkinson\u2019s, we will take a deeper look into the cognitive response, while for Alzheimer\u2019s, we will dive into the advantages of buntanetap for APOE4 carriers, addressing a pressing challenge in existing AD therapies.&#8221;<\/p>\n<p>Annovis will give two presentations and participate in a forum discussion:<\/p>\n<p>\n        <strong>Presentation: <\/strong>BUNTANETAP IMPROVES EARLY PARKINSON\u2019S PATIENTS\u2019 COGNITION AND MOTOR FUNCTIONS IN A PHASE 3 STUDY<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Date: <\/strong>April 1<\/li>\n<li>\n          <strong>Time: <\/strong>2:45 \u2013 3:00 pm CET<\/li>\n<li>\n          <strong>Presenter: <\/strong>Maria Maccecchini, Ph.D., Founder and CEO<\/li>\n<\/ul>\n<p>\n        <strong>Presentation:<\/strong> APOE4 AND BUNTANETAP IN PHASE II\/III ALZHEIMER\u2019S PATIENTS<\/p>\n<ul>\n<li>\n          <strong>Date: <\/strong>April 2<\/li>\n<li>\n          <strong>Time<\/strong>: 9:40 \u2013 9:55 am CET<\/li>\n<li>\n          <strong>Presenter<\/strong>: Cheng Fang, Ph.D., SVP, Research and Development<\/li>\n<\/ul>\n<p>\n        <strong>Forum: <\/strong>NOVEL APPROACHES TO ACCELERATE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES LINKED TO PD, LBD AND MSA<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Date: <\/strong>April 4<\/li>\n<li>\n          <strong>Time: <\/strong>4:20 \u2013 5:20 pm CET<\/li>\n<li>\n          <strong>Participant: <\/strong>Maria Maccecchini, Ph.D., Founder and CEO<\/li>\n<\/ul>\n<p>The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-YxnYm6jrir_194DS7UcP4BHZ5bTHt9jWNJOKG1dqaBZ-GevTCO0e9cacOtTAtRkzdS9YFydDFO059Ow5kepYQ==\" rel=\"nofollow\" target=\"_blank\">AD\/PD\u2122<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kjk3vCrH5-s0e_k8cnBr2CJlMWurOUzrJy6Djjbuc1wjDDTZilHxMHZfwnMTd5loIdkURAXo16Kb7zrUHjlaFQ==\" rel=\"nofollow\" target=\"_blank\">\u00a02025<\/a> conference brings together the brightest minds in the field in order to share the latest breakthroughs in treatment, translational R&amp;D, early diagnosis, drug development and clinical trials in AD, PD, and other related neurological disorders.<\/p>\n<p>\n        <strong>About Annovis <\/strong><br \/>\n        <br \/>Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kee5gR_ansfRVFxRTjgzC0bQrte1NQSUCQV7iUNyBhnJSA_jXLk57gH84DDdY6_12guOGvgRCR89azF68UmSRi_7RNbUvMO19MqAchYZ0KE=\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FLCCcc5fp5OvgthbdYHGexFsBZPQMr_QM7i0vSeikSg4VTZhgAzQd2D6v0dqsvv-HNdahJIRUfSBrBcJsgj2hWR0253-_slgkDzKkVcob82Vt5CNjWJeScD9ZJ3CUDC3dFZBad9wIf9_-s60BIlt7g==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tEKJGPKQ097p-8_22RMGCch4O0iH2Oq341URfWgJoRyv7XxA95361QZSs7mSVTaS27U71HZkuqvv6vOf7G5d7m-wJDNmPa1AY8lEKn1LqR4=\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-AzUgQ5N01w_BMz2GoY0Q_ecGuKv6i1vVA6-IAhH5FqxWMQFo6CqJzMS5-149f4CM_Mqn8K4mmTBAxzclJ99hw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Investor Alerts<\/strong><br \/>\n        <br \/>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vF6cA5gJyNvmlC5kJsoZofPHlfu_zjEY1iD87rjK223laGp3Z07ws-4RA0o-9pJpOz6CI7JAFsau1hOuvtDmXz-wColvG-WuVIIX0dwqhRW8xgs6J5lJVeYB9Iz0oLF4mzW2-8u0Ljeu9JmM8GpY_w==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.annovisbio.com\/email-alerts<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company\u2019s SEC filings under \u201cRisk Factors\u201d in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Annovis Bio Inc.<br \/>101 Lindenwood Drive<br \/>Suite 225<br \/>Malvern, PA 19355<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kee5gR_ansfRVFxRTjgzC6c5PiE95TkkV5eyEJktBPEfpQ6NDiZU7i4znlOgliKbRqFk7duOm2aNzjOcjMNuwN6zBatUcunxTzlg3Gt_q60=\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alexander Morin, Ph.D.<br \/>Director, Strategic Communications<br \/>Annovis Bio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6Jq-VQPX2EpA01UIxfPNy39cMYfmROmiDFgH7QTQ6U9-3v4fWF6dz0iZGEH8Hm65MV3DHAQ4JjzqSypbusFReEWq6KA0h4yXoz4hx0t-v7g=\" rel=\"nofollow\" target=\"_blank\">ir@annovisbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzIwMWE0MWEtNzJhZi00ZjdiLTg2Y2ItNjY2NDRjMzgyZjIxLTEyMDY0MDMtMjAyNS0wMy0yNS1lbg==\/tiny\/Annovis-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE: ANVS) (&#8220;Annovis&#8221;), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced its participation in the AD\/PD\u2122\u00a02025 taking place April 1-5 in Vienna. &#8220;We are at a pivotal moment in our company\u2019s journey as we have entered the late clinical stages for both Alzheimer\u2019s and Parkinson\u2019s. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications,\u201d commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. \u201cAt this meeting, we will present comprehensive data from our latest Phase 3 PD and Phase &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829364","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE: ANVS) (&#8220;Annovis&#8221;), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced its participation in the AD\/PD\u2122\u00a02025 taking place April 1-5 in Vienna. &#8220;We are at a pivotal moment in our company\u2019s journey as we have entered the late clinical stages for both Alzheimer\u2019s and Parkinson\u2019s. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications,\u201d commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. \u201cAt this meeting, we will present comprehensive data from our latest Phase 3 PD and Phase &hellip; Continue reading &quot;Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T12:05:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis to Attend AD\\\/PD\u2122\u00a02025 with Extensive Scientific Program\",\"datePublished\":\"2025-03-25T12:05:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/\"},\"wordCount\":482,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/\",\"name\":\"Annovis to Attend AD\\\/PD\u2122\u00a02025 with Extensive Scientific Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=\",\"datePublished\":\"2025-03-25T12:05:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis to Attend AD\\\/PD\u2122\u00a02025 with Extensive Scientific Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/","og_locale":"en_US","og_type":"article","og_title":"Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program - Market Newsdesk","og_description":"MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE: ANVS) (&#8220;Annovis&#8221;), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced its participation in the AD\/PD\u2122\u00a02025 taking place April 1-5 in Vienna. &#8220;We are at a pivotal moment in our company\u2019s journey as we have entered the late clinical stages for both Alzheimer\u2019s and Parkinson\u2019s. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications,\u201d commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. \u201cAt this meeting, we will present comprehensive data from our latest Phase 3 PD and Phase &hellip; Continue reading \"Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T12:05:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program","datePublished":"2025-03-25T12:05:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/"},"wordCount":482,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/","name":"Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=","datePublished":"2025-03-25T12:05:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQwOTY4MyM2ODMwODkyIzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-attend-ad-pd-2025-with-extensive-scientific-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis to Attend AD\/PD\u2122\u00a02025 with Extensive Scientific Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829364"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829364\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}